The Dharma, sutras, and commentarial interpretations of interest to American Buddhists of all traditions with news that not only informs but transforms. Emphasis on meditation, enlightenment, karma, social evolution, and nonharming.
(To contact us, leave a comment marked "private").
Monday, January 17, 2022
Battle over Psychedelic Therapy’s future
The Battle Over Psychedelic Therapy’s Future
(VICE News, Jan. 11, 2022) Psilocybin therapy is on the brink of becoming legally available in the US. But access isn’t guaranteed. There’s a struggle playing out right now between pharmaceutical companies (Big Pharma), nonprofits, and other entities over who gets to control and profit off the treatment. The outcome will determine whether the people most likely to benefit from psilocybin therapy will even be able to afford it.
Note: Manish Agrawal's name and title The Battle Over Psychedelic Therapy’s Future appear incorrectly at 19:19. Agrawal is the co-director of clinical research at Maryland Oncology Hematology.
All materials on this site are submitted by editors and readers. All images, unless otherwise noted, were taken from the Internet and are assumed to be in the public domain.
In the event that there is still a problem, issue, or error with copyrighted material, the break of the copyright is unintentional and noncommercial, and the material will be removed immediately upon presented proof.
Contact us by submitting a comment marked "private."
Do not follow this journal if you are under vinaya or parental restrictions. Secure protection by Sucuri.
Wisdom Quarterly: American Buddhist Journal is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 United States License. Permissions beyond the scope of this license may be available at creativecommons.org/about/licenses.
No comments:
Post a Comment